<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726514</url>
  </required_header>
  <id_info>
    <org_study_id>0100</org_study_id>
    <nct_id>NCT04726514</nct_id>
  </id_info>
  <brief_title>SleepFlexTM Treatment of Obstructive Sleep Apnea</brief_title>
  <official_title>SleepFlexTM Treatment of Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Berendo Scientific, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Berendo Scientific, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the SleepFlex&#xD;
      program for treatment of mild to moderate OSA&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from SleepFlex-related Serious Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the apnea-hypopnea index (AHI)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of side effects: mouth, throat, or neck pain; dysphagia</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Epworth Sleepiness Scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Outcomes of Sleep Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in supine AHI</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in non-supine AHI</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in percentage of breaths with snoring</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>App and device usability</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Program adherence and acceptance</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in fatigue</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in global quality of life</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>SleepFlex Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SleepFlex</intervention_name>
    <description>SleepFlex Program</description>
    <arm_group_label>SleepFlex Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21 years and older&#xD;
&#xD;
          -  Mild to moderate OSA, defined as AHI &gt;10 - 30 events/hour, documented by polysomnogram&#xD;
             or home sleep apnea test within 180 days prior to study enrollment&#xD;
&#xD;
          -  Central or mixed disordered breathing events (≤25% of total number of events)&#xD;
&#xD;
          -  Unable to tolerate or decline positive airway pressure therapy&#xD;
&#xD;
          -  Body mass index ≤32 kg/m2&#xD;
&#xD;
          -  Able to protrude tongue ≥20 mm beyond maxillary incisors&#xD;
&#xD;
          -  Absence of markedly enlarged tonsils, defined as 3+ or 4+ according to the Brodsky&#xD;
             classification&#xD;
&#xD;
          -  No uncontrolled sleep disorder other than OSA such as narcolepsy, chronic insomnia,&#xD;
             restless legs syndrome, or REM behavior disorder&#xD;
&#xD;
          -  Absence of excessive daytime sleepiness, defined by Epworth Sleepiness Scale score &gt;10&#xD;
&#xD;
          -  No uncontrolled nasal obstruction&#xD;
&#xD;
          -  Absence of moderate to severe mandibular insufficiency&#xD;
&#xD;
          -  No previous surgery involving the oral cavity or pharynx other than tonsillectomy&#xD;
&#xD;
          -  No previous radiation therapy to the head and neck&#xD;
&#xD;
          -  No known neurologic, cardiac (other than hypertension controlled with a single&#xD;
             medication), pulmonary, renal, hepatic, or psychiatric disorders&#xD;
&#xD;
          -  No psychiatric diagnoses other than treated depression or mild anxiety&#xD;
&#xD;
          -  Stable medication regimen for ≥1 month&#xD;
&#xD;
          -  No acute illness or infection&#xD;
&#xD;
          -  Ownership of personal smartphone with iOS or Android operating system&#xD;
&#xD;
          -  No known hypersensitivity to any material of the SleepFlex devices&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling or unable to provide informed written consent in English&#xD;
&#xD;
          -  Pregnancy, breastfeeding, or plans to become pregnant&#xD;
&#xD;
          -  Smoker (tobacco or recreational drugs) in the past month&#xD;
&#xD;
          -  Alcohol consumption, averaged over the previous month, greater than 2 alcoholic&#xD;
             beverages per day&#xD;
&#xD;
          -  Significant vision or hearing problems&#xD;
&#xD;
          -  Unwilling or incapable of returning for all follow-up visits and conduct sleep studies&#xD;
             at home, including the evaluation procedures and filling out questionnaires&#xD;
&#xD;
          -  Any other reason the investigator determines as being unfit for study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric J Kezirian, MD, MPH</last_name>
    <phone>14152358706</phone>
    <email>eric@sleepflex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tower Sleep Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Artal, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Tom Hoffman, RPSGT</last_name>
      <phone>310-657-4337</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>January 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

